| Dr James P Quenan, MD | |
|
265 Griffin St E, Amery, WI 54001-1439 | |
| (715) 268-8000 | |
| (715) 268-0308 |
| Full Name | Dr James P Quenan |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 265 Griffin St E, Amery, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770556227 | NPI | - | NPPES |
| P00251914 | Other | PALMETTO GBA RR MEDICARE | |
| 1016661 | Other | PREFERRED ONE | |
| 402G4QU | Other | BCBS MN | |
| 30106800 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 21309 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James P Quenan, MD 265 Griffin St E, Amery, WI 54001-1439 Ph: (715) 268-8000 | Dr James P Quenan, MD 265 Griffin St E, Amery, WI 54001-1439 Ph: (715) 268-8000 |
News Archive
New research led by Plymouth University Peninsula Schools of Medicine and Dentistry suggests that the cognitive test used in Alzheimer's drug trials is flawed.
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Benchmark Electronics, Inc. (NYSE: BHE), a leading contract manufacturing provider, announced sales of $510 million for the quarter ended September 30, 2009, compared to $642 million for the same quarter in the prior year. The Company reported third quarter net income of $16 million, or $0.25 per diluted share. In the comparable period of 2008, net income was $24 million, or $0.35 per diluted share.
Many prescriptions are sent to the pharmacy via electronic health record systems; however, correct routing of discontinued medications continues to be a problem, which increases the risk for medication safety events.
Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.
› Verified 4 days ago
Anders E Ulland, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 265 Griffin St E, Amery, WI 54001 Phone: 715-268-8000 Fax: 715-268-0311 | |
Dr. Linda S. Serna, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 265 Griffin St E, Amery, WI 54001 Phone: 715-268-8000 |